Skip to main content

Table 3 Her2,cMet, and FGFR2 statuses of patients and PDX models

From: Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

 

Patients

Patients/PDX models

Models

Age

Stage

Lauren

Her2

cMet

FGFR2

G01

≥60

III

Mixed

-/-

-/-

-/-

G03

≥60

III

Mixed

-/-

IHC(2+)/FISH(-)

FISH(+)

G05

<60

III

Intestinal

IHC(3+)/FISH(+)

-/-

-/-

G16

<60

III

Intestinal

-/-

-/-

-/-

G27

≥60

III

Diffuse

-/-

-/-

-/-

G29

<60

III

Intestinal

-/-

-/-

-/-

G30

<60

II

Intestinal

-/-

IHC(3+)/FISH(+)

-/-

G31

<60

III

Intestinal

-/-

IHC(2+)/FISH(+)

-/-

G32

≥60

III

Diffuse

-/-

-/-

-/-

G26a

≥60

III

Intestinal

IHC(2+)/FISH(-)

-/-

-/-

G28a

<60

III

Diffuse

-/-

-/-

-/-

G21a

≥60

III

Intestinal

-/-

-/-

-/-

G22b

<60

II

Intestinal

-/-

-/-

-/-

G23b

≥60

III

Intestinal

-/-

IHC(3+/0)/FISH(+/-)c

-/-

  1. aPDX models only transplanted to the second generation; bPDX models only transplanted to the first generation; cdiscordance of cMet status between primary tumors and xenografts in G23
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us